<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02769793</url>
  </required_header>
  <id_info>
    <org_study_id>16-2015-52</org_study_id>
    <nct_id>NCT02769793</nct_id>
  </id_info>
  <brief_title>Efficacy of Levodopa/Benserazide Dispersible Tablet on Response Fluctuations in PD Patients With Delayed ON</brief_title>
  <official_title>Efficacy of Levodopa/Benserazide Dispersible Tablet on Response Fluctuations in Parkinson's Disease Patients With Delayed ON: a Multicenter Randomized Open-label Cross-over Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>SMG-SNU Boramae Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether levodopa/benserazide dispersible is&#xD;
      effective in the adjunctive treatment of Parkinson's disease (PD) patients with delayed ON.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Delayed ON is one of the motor complications of advanced PD patients that effect of&#xD;
      anti-parkinsonian medication is delayed more than 40 minutes after intake. In the most severe&#xD;
      cases, the effect does not appear even until next medication schedule, so called &quot;No ON&quot;&#xD;
      status. It is important to manage delayed ON properly because it can interfere motor&#xD;
      functions and quality of life of PD patients.&#xD;
&#xD;
      Levodopa/benserazide dispersible can be absorbed rapidly in the intestine, so theoretically&#xD;
      it can break the poor response to conventional treatment of PD patients with delayed ON.&#xD;
      However, this has not been proven by clinical trials till now.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 2015</start_date>
  <completion_date type="Actual">December 2018</completion_date>
  <primary_completion_date type="Actual">August 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the time to ON after first morning dose using 3-day PD diary</measure>
    <time_frame>4 weeks</time_frame>
    <description>A specialized 3-day PD diary will be distributed to the patients 3 days prior to each visit. This diary will evaluate the latency of ON after intake of the study medication.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in the The Unified Parkinson Disease Rating Scale (UPDRS)</measure>
    <time_frame>4 weeks</time_frame>
    <description>a scale for assessment of parkinsonian symptom severity in PD patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the The Unified Dyskinesia Rating Scale (UDyskRS)</measure>
    <time_frame>4 weeks</time_frame>
    <description>a scale for assessment of levodopa-induced dyskinesia in PD patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the The Schwab &amp; England Activity of daily living scale (SEADL)</measure>
    <time_frame>4 weeks</time_frame>
    <description>a scale for activity of daily living assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the The Parkinson Disease Questionnaire-39 (PDQ-39)</measure>
    <time_frame>4 weeks</time_frame>
    <description>a scale for health-related quality of life in PD patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Patient global improvement (PGI)</measure>
    <time_frame>4 weeks</time_frame>
    <description>patient-centered assessment of global improvement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Clinician global improvement (CGI)</measure>
    <time_frame>4 weeks</time_frame>
    <description>clinician's assessment for global improvement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the K-Minimental status examination (K-MMSE)</measure>
    <time_frame>4 weeks</time_frame>
    <description>global cognition assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Total ON time, total OFF time using 3-day PD diary</measure>
    <time_frame>4 weeks</time_frame>
    <description>a severity assessment index for PD patients with motor fluctuation</description>
  </secondary_outcome>
  <other_outcome>
    <measure>relationship between delayed ON and response to investigational drugs and the Helicobactor pylori serology and index for atrophic gastritis</measure>
    <time_frame>at baseline and after 4 weeks of each treatment arm</time_frame>
    <description>whether delayed ON and treatment response are affected by H.pylori status</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>Levodopa dispersible</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Levodopa dispersible 100mg/tablet, PO, 1 tablet in the morning, once daily for 4 weeks (crossover)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Levodopa</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Levodopa 100mg/tablet, PO, 1 tablet in the morning, once daily for 4 weeks (crossover)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levodopa dispersible</intervention_name>
    <description>Levodopa dispersible 100mg/tablet, PO, 1 tablet in the morning, once daily for 4 weeks (crossover)</description>
    <arm_group_label>Levodopa dispersible</arm_group_label>
    <other_name>Madopar dispersible</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levodopa</intervention_name>
    <description>Levodopa 100mg/tablet, PO, 1 tablet in the morning, once daily for 4 weeks (crossover)</description>
    <arm_group_label>Levodopa</arm_group_label>
    <other_name>Madopar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female patients between 31 and 80 years&#xD;
&#xD;
          -  Parkinson disease (PD) was diagnosed by United Kingdom Parkinson disease brain bank&#xD;
             criteria&#xD;
&#xD;
          -  Patients receiving stable Levodopa treatment at least 2 weeks prior to baseline visit&#xD;
&#xD;
          -  Delayed ON was confirmed by a specialized PD diary that records change in motor&#xD;
             symptoms 90 minute after the first morning dose. Delayed ON is defined as delay of&#xD;
             more than 40 minutes after the first morning dose for resolution of OFF state or&#xD;
             experience of no ON state at least 1 per week.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Existence of cognitive decline hard to participate in the clinical trial or&#xD;
             K-Minimental Status Exam score 24 or less&#xD;
&#xD;
          -  Any contraindication of blood sampling&#xD;
&#xD;
          -  Subjects with clinically significant psychiatric illness&#xD;
&#xD;
          -  Subjects with a cancer or severe medical illness&#xD;
&#xD;
          -  Lactating, pregnant, or possible pregnant&#xD;
&#xD;
          -  History of malignant melanoma&#xD;
&#xD;
          -  Subjects with narrow-angle glaucoma&#xD;
&#xD;
          -  Subjects with hypersensitivity to levodopa or benserazide&#xD;
&#xD;
          -  Subjects treated with non-selective monoamine oxidase (MAO)-B inhibitors&#xD;
&#xD;
          -  Subjects with peptic ulcer, colitis, or gastrointestinal disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>31 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jee-Young Lee, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>SMG-SNU Boramae Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SMG-SNU Boramae Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 9, 2016</study_first_submitted>
  <study_first_submitted_qc>May 10, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2016</study_first_posted>
  <last_update_submitted>May 4, 2021</last_update_submitted>
  <last_update_submitted_qc>May 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Jee-Young Lee</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levodopa</mesh_term>
    <mesh_term>Benserazide</mesh_term>
    <mesh_term>Benserazide, levodopa drug combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

